Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Hydroxychloroquine to be administered intra-arterially at time of transarterial embolization as well as orally for 6 weeks following the procedure

Lipiodol is an FDA-approved drug delivered agent and embolic which is administered as standard of care for transarterial embolization for hepatocellular carcinoma. Lipiodol will be administered intra-arterially in both arms at the time of procedure.

Placebo will be administered orally for 6 weeks following the procedure to patients in arm 2